Private equity activity in the pharmaceutical industry in France remained flat in 2023

In value terms, private equity deal activity in France increased by 8% in Q2 2023 compared with the previous quarter’s total of $101.1m and rose by 307% as compared to Q2 2022. Related deal volume remained flat in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.

The top-ranked financial advisors supporting these private equity deals in France in Q2 2023 were Clearwater International Ltd (France); Deloitte Conseil; Germain Maureau with 1, 1, 1 deals respectively.

The top-ranked legal advisorss supporting these private equity deals in France Q2 2023 were McDermott Will & Emery; CMS Legal Services EEIG; DLA Piper with 2, 1, 1 deals respectively.

For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.